FX steady, stocks higher as markets await trade progress, rate decisions
Markets watching tariffs, Philippine president to meet Trump
Singapore stocks hit record high for 14th session
MSCI EM FX down 0.1%, stocks up 0.2%
July 21 (Reuters) - Most emerging market currencies steadied while stocks were mixed on Monday as investors awaited trade developments in the U.S. and central bank decisions in emerging Europe.
Markets took a breather after a week packed with concerns over trade tariffs impacting U.S. inflation and worries over the Federal Reserve's independence as President Donald Trump kept open the possibility of firing chair Jerome Powell.
Most EM currencies stabilized, with South Africa's rand 0.1% higher against the greenback, while Turkey's lira was little changed.
Russia's rouble bounced back by 0.5% against the dollar, over-the-counter market data showed. The currency fell 0.8% in the previous session after the European Union agreed an 18th package of sanctions against Russia.
Currencies in emerging Europe were subdued against the euro. Central banks in Hungary, Turkey and Russia are scheduled to announce interest rate decisions this week.
MSCI's gauge tracking global EM currencies was down 0.1%, after logging declines for the last two weeks.
"Emerging markets moved following the U.S. CPI report and comments from Trump that he would want to fire Powell... now it's just a period of calm," said Giulia Bellicoso, markets economist at Capital Economics.
Meanwhile, investors kept an eye on any trade developments with the United States. The Philippine president is meeting Trump this week, hoping to clinch a trade deal.
Only the UK, China, Indonesia and Vietnam have agreed a trade deal with the U.S. since Trump's sweeping duties roiled global markets, however, investors are betting on more ahead of the revised August 1 deadline.
"If tariffs were to come into effect, it would be a big shock for markets as they're cautiously optimistic about the outlook and still hope for negotiations," said Bellicoso.
Stocks in emerging markets were slightly higher, with MSCI's global EM stocks index up 0.2% on the day.
Bourses in Hungary and Romania were down 0.3% and 0.5% respectively, while South African stocks were up 0.4%.
Ones in Turkey gained 1.8%, trading at their highest levels since March 17.
Gains came in from heavyweight Asian stocks, with Singapore's index touching a record high for a 14th consecutive session. The local central bank plans to place about S$ 1.1 billion with asset managers to boost the stock market.
The yuan eased slightly against the dollar after China's central bank left benchmark lending rates unchanged, in line with market expectations.
** Trump, Xi might meet ahead of or during October APEC summit in South Korea, SCMP reports
** Congo, M23 rebels pledge in Qatar to reach peace deal next month
** Zambia sees economic growth picking up to 6.4% next year
For TOP NEWS across emerging markets
For CENTRAL EUROPE market report, see
For TURKISH market report, see
For RUSSIAN market report, see (Reporting by Purvi Agarwal and Ankita Yadav in Bengaluru Editing by Christina Fincher)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
29 minutes ago
- Mint
Indian shares inch lower as Kotak earnings drag financials, trade deal delay weighs
By Bharath Rajeswaran and Vivek Kumar M (Reuters) -Indian shares inched lower on Monday as weak results from Kotak Mahindra Bank weighed on sentiment, while uncertainty over trade talks with the U.S. added to overall caution. The Nifty 50 fell 0.16% to 24,798.9 points and the BSE Sensex lost 0.2% to 81,325.4 as of 10:03 a.m. IST. The broader small-caps and mid-caps lost 0.3% and 0.2%, respectively. Negotiations between India and the United States remained deadlocked over tariff cuts on agriculture and dairy products, dimming hopes of an interim deal ahead of U.S. President Donald Trump's August 1 deadline. This is in contrast to a framework trade agreement struck between the U.S. and European Union over the weekend, easing fears of a bigger trade war between the two allies, which account for almost a third of global trade. High-weightage financials and private banks lost 0.2% and 1%, respectively, dragged by a 7% fall in Kotak Mahindra Bank after it posted a drop in quarterly profit. The IT index lost 0.5%, with Tata Consultancy Services shedding 1.6% after it announced plans to reduce its workforce by 2% in fiscal year 2026. The Nifty 50 and 30-stock Sensex have logged four consecutive weekly losses due to weak earnings, foreign outflows and uncertainty over the U.S.-India trade deal. "A dull earnings season and the lingering delay in the India-U.S. trade deal have clearly cast a shadow on market sentiment. With valuations still stretched across the board, investors are understandably treading with heightened caution," said G Chokkalingam, founder and head of research at Equinomics Research. Among individual stocks, Mphasis gained 2.4% on posting quarterly results in-line with estimates and on strong deal bookings, which has boosted the IT company's revenue growth outlook. SBI Cards and Payment Services lost 3.7% after missing profit estimates in the June quarter. (Reporting by Vivek Kumar M and Bharath Rajeswaran; Editing by Eileen Soreng and Mrigank Dhaniwala)
Economic Times
29 minutes ago
- Economic Times
Market in consolidation mode; triggers needed, says Sunil Subramaniam
Tired of too many ads? Remove Ads Tired of too many ads? Remove Ads "Another reason for pharma's past underperformance is that FIIs were driving the selling pressure. They closely track export-oriented sectors. So the recent post-results bounce in pharma is largely driven by DIIs. FIIs still haven't firmed up their stance on India. They remain a bit cautious, especially because the delay in the BTA (Bilateral Trade Agreement) hasn't helped sentiment," says Sunil Subramaniam , Market like you said, the question is—why were they under pressure in the first place? I'd call it the Trump effect. Mr. Trump has been talking a lot about imposing heavy pharma tariffs. He hasn't actually done anything yet, but every time he makes such statements, it creates nervousness—whether he's targeting CDMO players or generics, and how he plans to go about it. That uncertainty has impacted the pharma sector, putting it under when individual companies are reporting good numbers, the market has no choice but to buy into them—because at least those companies are indicating a positive outlook. Plus, some of them may not even be impacted by tariffs, creating a window of opportunity. Also, the pharma space includes domestic-oriented businesses like hospitals and diagnostics, which are unaffected by U.S. tariff issues. So overall, pharma remains a defensive reason for pharma's past underperformance is that FIIs were driving the selling pressure. They closely track export-oriented sectors. So the recent post-results bounce in pharma is largely driven by DIIs. FIIs still haven't firmed up their stance on India. They remain a bit cautious, especially because the delay in the BTA (Bilateral Trade Agreement) hasn't helped we need to understand the market's movement over the last three months. Post-March, FIIs were actually buyers in April and May, and even in June, though to a lesser extent. Meanwhile, if you look at the end of March, mutual fund DIIs—especially domestic mutual funds—had built up cash positions to around 7.25% of their April and May, both mutual funds and FIIs were buying, which supported the market. But starting this month, mutual fund cash levels are back down to around 5%, which is close to their lower limit. That means DIIs don't have as much cash left to deploy, apart from the fresh SIP looking at last earnings season and market levels, domestic funds have largely deployed their cash. FIIs, on the other hand, had expected some action around the BTA by July 9, which then got pushed to August 1. But now, even that deadline seems unlikely to be met. The Indian trade delegation has returned from the U.S. without a deal. Sticking points remain—like agriculture—and they won't be easy to the question now is whether Trump will extend the 10% tariff pause beyond August 1 or slap a 26% tariff on India and then negotiate, like he did with Japan—imposing higher tariffs first and then signing a deal at 19%. That kind of uncertainty around the India-U.S. BTA is keeping FIIs factor is China. While China and the U.S. haven't signed a full BTA either, they seem to have reached some understanding. Meanwhile, China's markets have been beaten down so much that the one-year forward P/E is around 11—compared to India's 22. And China's economy is about 4.5 times larger than India's. Even at 4% growth, those are big numbers. So FIIs are starting to see more value in China, pulling some attention away from as for your question on the next trigger—clearly, a breakthrough on the BTA front, like an interim deal or assurance that tariffs will be capped below 20%, could bring FIIs back. On the domestic side, it's the ongoing earnings season. Results have been mixed. The IT sector, for instance, didn't post terrible earnings, but weak guidance is weighing heavily, especially in the absence of FII DIIs have already used most of their cash, their incremental buying will depend on the inflow from SIPs and earnings results. So companies with strong earnings and forward guidance will likely get DII if the early festival season gives good signs on the consumption front, that could also be a positive trigger. Until then, expect the market to remain in a sideways, consolidative phase for some time.
Indian Express
29 minutes ago
- Indian Express
Who is eligible for US visa interview waiver? Key changes, additional criteria — all you need to know
The US Department of State has unveiled significant changes to its visa interview waiver policy, effective September 2. This would include all non-immigrant visa applicants, including those under the age of 14 and over 79 years, to attend an in-person interview with a consular officer. The non-immigrant visa categories include tourist and business visas (B-1/B-2), student visas (F and M), work visas (H-1B), and exchange visas (J). Diplomatic visas fall under categories A and G. The latest update on July 25, which aims to enhance security, has raised concerns among H-1B visa holders and other nonimmigrant visa categories about increased waiting time and processing delays. All nonimmigrant visa applicants, including applicants under the age of 14 and over the age of 79, will generally require an in-person interview with a consular officer, except for the following categories: To qualify for an interview waiver, applicants must: The US Citizenship and Immigration Services emphasised that even with potential interview waivers, consular officers retained the discretion to interview the applicant on a case-by-case basis for any reason. This supersedes the Interview Waiver Update of February 18, 2025. 'Consular officers may still require in-person interviews on a case-by-case basis for any reason. Applicants should check embassy and consulate websites for more detailed information about visa application requirements and procedures, and to learn more about the embassy or consulate's operating status and services,' the US Citizenship and Immigration Services (USCIS) said in its release. Earlier this month, the US also introduced a new $250 Visa Integrity Fee, which takes effect in 2026. Designed as a form of security deposit, the fee is pegged to inflation and may be refunded if visa holders meet specific compliance criteria. This is part of Trump's sweeping immigration overhaul, under the recently signed One Big Beautiful Bill Act, enacted on July 4.
